Cargando…

Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer

BACKGROUND: We report the clinical activity, safety, and identification of a predictive biomarker for bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of TGFβRII (a TGF-β “trap”) fused to a human IgG1 mAb blocking PD-L1, in patients with advanced tri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spira, Alexander, Awada, Ahmad, Isambert, Nicolas, Lorente, David, Penel, Nicolas, Zhang, Yue, Ojalvo, Laureen S., Hicking, Christine, Rolfe, P. Alexander, Ihling, Christian, Dussault, Isabelle, Locke, George, Borel, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773992/ https://www.ncbi.nlm.nih.gov/pubmed/36568239 http://dx.doi.org/10.3389/fonc.2022.981940

Ejemplares similares

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
por: Cho, Byoung Chul, et al.
Publicado: (2020)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
por: Tan, Benjamin, et al.
Publicado: (2021)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
por: Barlesi, Fabrice, et al.
Publicado: (2022)

Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF‐β and PD‐L1
por: Vugmeyster, Yulia, et al.
Publicado: (2020)

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma
por: Khasraw, Mustafa, et al.
Publicado: (2021)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses
por: Lan, Yan, et al.
Publicado: (2022)

Immune correlates of clinical parameters in patients with HPV-associated malignancies treated with bintrafusp alfa
por: Tsai, Yo-Ting, et al.
Publicado: (2022)

Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
por: Yoo, Changhoon, et al.
Publicado: (2020)

NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
por: Xu, Chunxiao, et al.
Publicado: (2021)

Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia
por: Lin, Chia-Chi, et al.
Publicado: (2021)

Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
por: Spira, Alexander, et al.
Publicado: (2022)

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
por: Ozawa, Yohei, et al.
Publicado: (2021)

Observational Study of PD-L1, TGF-β, and Immune Cell Infiltrates in Hepatocellular Carcinoma
por: Ihling, Christian, et al.
Publicado: (2019)

Bullous pemphigoid secondary to bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1
por: Wiggins, Claire J., et al.
Publicado: (2021)

Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
por: Yoo, Changhoon, et al.
Publicado: (2023)

Efficacy, safety, and correlative biomarkers of bintrafusp alfa in recurrent or metastatic nasopharyngeal cancer patients: a phase II clinical trial
por: Chiang, Chi Leung, et al.
Publicado: (2023)

Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer
por: Morris, Van K., et al.
Publicado: (2022)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

A multistate modeling and simulation framework to learn dose–response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
por: Liu, Han, et al.
Publicado: (2023)

Erratum: The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
Publicado: (2020)

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
por: Vugmeyster, Yulia, et al.
Publicado: (2022)

Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety‐Assessment Cohort
por: Doi, Toshihiko, et al.
Publicado: (2020)

Correction: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Publicado: (2020)

HMGA2 Supports Cancer Hallmarks in Triple-Negative Breast Cancer
por: Mansoori, Behzad, et al.
Publicado: (2021)

HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells
por: Shah, Sandeep N., et al.
Publicado: (2013)

MicroRNA-150 suppresses triple-negative breast cancer metastasis through targeting HMGA2
por: Tang, Wentao, et al.
Publicado: (2018)

ALFA
por: Hiller, Karlheinz
Publicado: (2012)

HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma
por: Sterenczak, Katharina Anna, et al.
Publicado: (2014)

An open or closed case for HMGA
por: Williams, Ruth
Publicado: (2006)

HMGA1-pseudogenes and cancer
por: De Martino, Marco, et al.
Publicado: (2016)

HMGA Proteins in Hematological Malignancies
por: Minervini, Angela, et al.
Publicado: (2020)

Prognostic significance of high mobility group A2 (HMGA2) in pancreatic ductal adenocarcinoma: malignant functions of cytoplasmic HMGA2 expression
por: Gundlach, Jan-Paul, et al.
Publicado: (2021)

Hmga1/Hmga2 double knock-out mice display a “superpygmy” phenotype
por: Federico, Antonella, et al.
Publicado: (2014)

The Fragment HMGA2-sh-3p20 from HMGA2 mRNA 3′UTR Promotes the Growth of Hepatoma Cells by Upregulating HMGA2
por: Wang, Yuan, et al.
Publicado: (2017)

Recombinant follitropin alfa/lutropin alfa in fertility treatment
por: Gibreel, Ahmed, et al.
Publicado: (2010)

A Study of Diffractive Scattering with the ATLAS and ALFA Experiment
por: Lind, Alexander Pedersen
Publicado: (2017)

WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer
por: Wend, Peter, et al.
Publicado: (2013)

HMGA Genes and Proteins in Development and Evolution
por: Vignali, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_56a7v3k7c1ktvmmtdufk3m3f07